{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:18:45Z","timestamp":1783055925751,"version":"3.54.6"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002467","name":"Dankook University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002467","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cbi.2026.112117","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:47:19Z","timestamp":1777535239000},"page":"112117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Integrin-targeting cyclic peptides suppress TGF-\u03b21\u2013driven EMT and invasion in third-generation EGFR-TKI\u2013resistant NSCLC"],"prefix":"10.1016","volume":"434","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8288-2807","authenticated-orcid":false,"given":"Jay","family":"Seo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7509-5313","authenticated-orcid":false,"given":"Jiyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cbi.2026.112117_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.suc.2021.12.001","article-title":"Lung cancer: epidemiology and screening","volume":"102","author":"Oliver","year":"2022","journal-title":"Surg Clin North Am"},{"issue":"7689","key":"10.1016\/j.cbi.2026.112117_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.cbi.2026.112117_bib3","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1038\/s41586-018-0228-6","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"559","year":"2018","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cbi.2026.112117_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.cbi.2026.112117_bib5","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.cbi.2026.112117_bib6","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.cbi.2026.112117_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cbi.2026.112117_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.cbi.2026.112117_bib9","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/1535-7163.MCT-18-0976","article-title":"Mutant-selective irreversible EGFR inhibitor, naquotinib, inhibits tumor growth in NSCLC models with EGFR-activating mutations, T790M mutation, and AXL overexpression","volume":"18","author":"Tanaka","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"7276","key":"10.1016\/j.cbi.2026.112117_bib10","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/nature08622","article-title":"Novel mutant selective EGFR kinase inhibitors against EGFR T790M","volume":"462","author":"Zhou","year":"2009","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.cbi.2026.112117_bib11","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa1413654","article-title":"Rociletinib in EGFR-mutated non-small-cell lung cancer","volume":"372","author":"Sequist","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.cbi.2026.112117_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd generation EGFR TKI resistance in advanced non-small-cell lung cancer","volume":"59","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.cbi.2026.112117_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: the constant battle","volume":"116","author":"Zalaquett","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.cbi.2026.112117_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open-label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.cbi.2026.112117_bib15","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1111\/cas.13763","article-title":"Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small-cell lung cancer","volume":"109","author":"Sato","year":"2018","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.cbi.2026.112117_bib16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.cllc.2012.12.001","article-title":"Preclinical rationale for PI3K\/Akt\/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer","volume":"14","author":"Gadgeel","year":"2013","journal-title":"Clin. Lung Cancer"},{"issue":"12","key":"10.1016\/j.cbi.2026.112117_bib17","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.21037\/tcr-23-956","article-title":"Clinical advances in EGFR-TKI combination therapy for EGFR-mutated NSCLC: a narrative review","volume":"12","author":"Zhang","year":"2023","journal-title":"Transl. Cancer Res."},{"issue":"2","key":"10.1016\/j.cbi.2026.112117_bib18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/acs.jmedchem.1c00876","article-title":"Emerging approaches to overcome acquired drug resistance obstacles to osimertinib in non-small-cell lung cancer","volume":"65","author":"Shaikh","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cbi.2026.112117_bib19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","article-title":"RGD and other recognition sequences for integrins","volume":"12","author":"Ruoslahti","year":"1996","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"8","key":"10.1016\/j.cbi.2026.112117_bib20","first-page":"813","article-title":"Disintegrins: RGD-containing proteins which inhibit cell\/matrix interactions (adhesion) and cell\/cell interactions (aggregation) via the integrin receptors","volume":"40","author":"Williams","year":"1992","journal-title":"Pathol. Biol."},{"issue":"2","key":"10.1016\/j.cbi.2026.112117_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrc727","article-title":"Role of integrins in cell invasion and migration","volume":"2","author":"Hood","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"39","key":"10.1016\/j.cbi.2026.112117_bib22","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1038\/onc.2011.107","article-title":"\u03b21 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells","volume":"30","author":"Morello","year":"2011","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.cbi.2026.112117_bib23","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.apsb.2021.01.004","article-title":"Integrins as attractive targets for cancer therapeutics","volume":"11","author":"Li","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.cbi.2026.112117_bib24","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/jcb.22888","article-title":"Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer","volume":"111","author":"Ju","year":"2010","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.cbi.2026.112117_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6800","article-title":"RGD peptide in cancer targeting: benefits, challenges, solutions, and possible integrin-RGD interactions","volume":"13","author":"Javid","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.cbi.2026.112117_bib26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.drup.2005.10.002","article-title":"RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature","volume":"8","author":"Temming","year":"2005","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.cbi.2026.112117_bib27","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/187152010794728639","article-title":"Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation","volume":"10","author":"Mas-Moruno","year":"2010","journal-title":"Anti Cancer Agents Med. Chem."},{"issue":"3","key":"10.1016\/j.cbi.2026.112117_bib28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2217\/fon.11.8","article-title":"Cilengitide: an RGD pentapeptide \u03b1v\u03b23 and \u03b1v\u03b25 integrin inhibitor in development for glioblastoma and other malignancies","volume":"7","author":"Reardon","year":"2011","journal-title":"Future Oncol."},{"issue":"8","key":"10.1016\/j.cbi.2026.112117_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127039","article-title":"Novel cilengitide-based cyclic RGD peptides as \u03b1v\u03b23 integrin inhibitors","volume":"30","author":"Meena","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.cbi.2026.112117_bib30","first-page":"3499","article-title":"RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells","volume":"6","author":"Cai","year":"2011","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.cbi.2026.112117_bib31","article-title":"Cyclic pentapeptide cRGDfK enhances the inhibitory effect of sunitinib on TGF-\u03b21-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells","volume":"15","author":"Park","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2026.112117_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.639095","article-title":"Cyclic RGD pentapeptide cilengitide enhances efficacy of gefitinib on TGF-\u03b21-induced epithelial-to-mesenchymal transition and invasion in human non-small cell lung cancer cells","volume":"12","author":"Jeong","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2026.112117_bib33","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.3390\/ijms23073423","article-title":"Combination effect of cilengitide with erlotinib on TGF-\u03b21-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells","volume":"23","author":"Jeong","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2026.112117_bib34","article-title":"Synthesis and biological evaluation of cilengitide derivatives on TGF-\u03b21-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells","volume":"114","author":"Park","year":"2022","journal-title":"Pep Sci"},{"key":"10.1016\/j.cbi.2026.112117_bib35","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/bkcs.12601","article-title":"Combination effect of cilengitide derivatives with gefitinib on TGF-\u03b21-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells","volume":"43","author":"Seo","year":"2022","journal-title":"Bull Korean Chem Soc"},{"key":"10.1016\/j.cbi.2026.112117_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1277199","article-title":"Effects of cilengitide derivatives on TGF-\u03b21-induced epithelial-to-mesenchymal transition and invasion in gefitinib-resistant non-small cell lung cancer cells","volume":"14","author":"Seo","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2026.112117_bib37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbcan.2018.10.003","article-title":"EMT: a mechanism for escape from EGFR-targeted therapy in lung cancer","volume":"1871","author":"Tulchinsky","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.cbi.2026.112117_bib38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.cbi.2026.112117_bib39","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10555-012-9375-7","article-title":"TGF-\u03b2 signalling and its role in cancer progression and metastasis","volume":"31","author":"Drabsch","year":"2012","journal-title":"Cancer Metastasis Rev."},{"issue":"2","key":"10.1016\/j.cbi.2026.112117_bib40","doi-asserted-by":"crossref","first-page":"172","DOI":"10.21037\/tlcr.2016.04.07","article-title":"The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer","volume":"5","author":"Jakobsen","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.cbi.2026.112117_bib41","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1158\/0008-5472.CAN-12-4136","article-title":"Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells","volume":"73","author":"Shien","year":"2013","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.cbi.2026.112117_bib42","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1038\/s41596-019-0160-8","article-title":"High-resolution 3D imaging of fixed and cleared organoids","volume":"14","author":"Dekkers","year":"2019","journal-title":"Nat. Protoc."},{"issue":"9","key":"10.1016\/j.cbi.2026.112117_bib43","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2174\/15680096113136660102","article-title":"The role of snail in EMT and tumorigenesis","volume":"13","author":"Wang","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1\u20132","key":"10.1016\/j.cbi.2026.112117_bib44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11010-011-0869-3","article-title":"Transforming growth factor-\u03b21 promotes lung adenocarcinoma invasion and metastasis by epithelial-to-mesenchymal transition","volume":"355","author":"Zhang","year":"2011","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.cbi.2026.112117_bib45","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212\u0394\u0394C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.cbi.2026.112117_bib46","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1016\/j.apsb.2021.01.004","article-title":"Integrins as attractive targets for cancer therapeutics","volume":"11","author":"Li","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.cbi.2026.112117_bib47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00690290","article-title":"Fibronectin and integrins in invasion and metastasis","volume":"14","author":"Akiyama","year":"1995","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/j.cbi.2026.112117_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/dvg.23529","article-title":"Epithelial-mesenchymal plasticity in kidney fibrosis","volume":"62","author":"Hadpech","year":"2024","journal-title":"Genesis"},{"key":"10.1016\/j.cbi.2026.112117_bib49","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/761820","article-title":"Peptide-based treatment: a promising cancer therapy","volume":"2015","author":"Xiao","year":"2015","journal-title":"J. Immunol. Res."},{"issue":"1","key":"10.1016\/j.cbi.2026.112117_bib50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40290-018-0261-7","article-title":"Peptide-based therapeutics for oncology","volume":"33","author":"Fisher","year":"2019","journal-title":"Pharm. Med. (Lond.)"},{"issue":"5","key":"10.1016\/j.cbi.2026.112117_bib51","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1007\/s13277-014-1643-4","article-title":"Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol"},{"issue":"4","key":"10.1016\/j.cbi.2026.112117_bib52","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3892\/mco.2014.289","article-title":"Association of serum hemoglobin A1c, C-peptide and insulin-like growth factor-1 levels with the occurrence and development of lung cancer","volume":"2","author":"Zhang","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.cbi.2026.112117_bib53","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1038\/srep04480","article-title":"Identification and characterization of a suite of tumor targeting peptides for non-small cell lung cancer","volume":"4","author":"McGuire","year":"2014","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.cbi.2026.112117_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096029","article-title":"Peptides from the variable region of specific antibodies are shared among lung cancer patients","volume":"9","author":"de Costa","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cbi.2026.112117_bib55","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2014.05.004","article-title":"Identification of stem-like cells in non-small cell lung cancer cells with specific peptides","volume":"351","author":"Wang","year":"2014","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.cbi.2026.112117_bib56","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.biomaterials.2013.08.091","article-title":"Suppression of colorectal cancer subcutaneous xenograft and experimental lung metastasis using nanoparticle-mediated drug delivery to tumor neovasculature","volume":"35","author":"Wang","year":"2014","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.cbi.2026.112117_bib57","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2012.11.005","article-title":"Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers","volume":"49","author":"Takahashi","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.cbi.2026.112117_bib58","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2014.07.018","article-title":"A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide","volume":"86","author":"Kotsakis","year":"2014","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.cbi.2026.112117_bib59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1593\/neo.14182","article-title":"Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts","volume":"16","author":"Ahsan","year":"2014","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.cbi.2026.112117_bib60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.intimp.2014.05.001","article-title":"A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock","volume":"21","author":"Sigalov","year":"2014","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.cbi.2026.112117_bib61","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ejpb.2014.06.020","article-title":"Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles","volume":"88","author":"Chittasupho","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"24","key":"10.1016\/j.cbi.2026.112117_bib62","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.1016\/j.biomaterials.2014.04.016","article-title":"Delivery of platinum(IV) drug to subcutaneous tumor and lung metastasis using bradykinin-potentiating peptide-decorated chitosan nanoparticles","volume":"35","author":"Wang","year":"2014","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.cbi.2026.112117_bib63","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5963","key":"10.1016\/j.cbi.2026.112117_bib64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/309030a0","article-title":"Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule","volume":"309","author":"Pierschbacher","year":"1984","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.cbi.2026.112117_bib65","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0945-053X(03)00083-0","article-title":"The RGD story: a personal account","volume":"22","author":"Ruoslahti","year":"2003","journal-title":"Matrix Biol."},{"issue":"3","key":"10.1016\/j.cbi.2026.112117_bib66","first-page":"265","article-title":"Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins","volume":"13","author":"Koivunen","year":"1995","journal-title":"Biotechnol."},{"issue":"5","key":"10.1016\/j.cbi.2026.112117_bib67","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/protein\/gzh055","article-title":"Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells","volume":"17","author":"H\u00f6lig","year":"2004","journal-title":"Protein Eng Des Sel"}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279726002255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279726002255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:44:30Z","timestamp":1783053870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279726002255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":67,"alternative-id":["S0009279726002255"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2026.112117","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrin-targeting cyclic peptides suppress TGF-\u03b21\u2013driven EMT and invasion in third-generation EGFR-TKI\u2013resistant NSCLC","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2026.112117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112117"}}